Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People

Exclusion Criteria

• •CD4 count of 250 cells/mm3 or greater
• •Negative HBsAb, HBsAg, and HBcAb
• •Willing to use acceptable forms of contraception while on study treatment and for 24 weeks after study treatment has ended
• •Cancer. Participants with squamous cell or basal cell skin cancer are not excluded.
• •Autoimmune disease
• •Immunosuppressive medications. People who use or have used corticosteroid nasal sprays are not excluded. People who have received fewer than 2 weeks of systemic corticosteroids with the last dose over a month prior to study entry are not excluded.
• •Any medical or psychiatric condition or occupational responsibilities that may interfere with the study
• •Immunomodulator or investigational agent therapy within 30 days prior to study entry
• •Allergy/sensitivity to study drugs or their formulations, including thimerosal
• •Current drug or alcohol use that, in the opinion of the investigator, would interfere with the study
• •Active hepatitis C virus infection, as indicated by serum antibodies to HCV AND detectable HCV RNA in plasma
• •Blood clotting abnormalities
• •Any other condition that, in the opinion of the investigator, might interfere with the study
• •Pregnancy or breastfeeding